- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00001911
Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections
This study will test the safety and effectiveness of a drug called interleukin-12 (IL-12) in fighting severe infectious (other than tuberculosis) caused by a group of bacteria called mycobacteria. IL-12 is similar to a substance the body produces naturally to strengthen immune function (infection-fighting ability). It works by stimulating white blood cells to increase production of a chemical called interferon gamma, which can improve or cure mycobacterial infections in some patients.
In previous studies, IL-12 has improved immune function against mycobacteria in test tube experiments and in mice. A recent study of three patients with mycobacterial infections treated with the drug showed encouraging results. The drug has also been studied more extensively in patients with cancer, HIV infection and hepatitis C.
Patients in this study will receive IL-12 injections under the skin twice a week for one year. They will be taught how to self-administer the drug, but a home care nurse or a physician may also give the injections. The drug dosage will be increased each week to determine the safest and most effective dose for fighting this infection. If intolerable side effects develop at a certain dose, the previous dose level will be used for the next injection. That dose will then be used for the rest of the study, unless unacceptable side effects develop at that level, in which case the dose will again be lowered. Patients will receive an antibiotic against mycobacteria.
Physical examinations and blood and urine tests will be done once a month for at least the first year and then every 3 months the following year to evaluate kidney, liver, and immune function. The first evaluation-at the start of the study-is done on an inpatient basis.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Inscripción
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892
- National Institute of Allergy and Infectious Diseases (NIAID)
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Severe disseminated or pulmonary nontuberculous mycobacterial infection refractory to the best tolerated conventional therapy in addition to IFN gamma delivered for at least 3 months. This infection must have been proven by culture at some point during the illness. At the time of enrollment, patients will be eligible if they have negative cultures but histopathologic, examinable, or radiographic evidence of ongoing infection.
In vitro responsiveness to IL-12 as demonstrated by augmentation of peripheral blood mononuclear cell (PBMC) phytohemagglutinin (PHA) induced IFN gamma production.
Women of childbearing age must have a negative pregnancy test (urine or serum) at the time of starting the study and agree to take measures to avoid pregnancy throughout the study while receiving IL-12. Males will be advised that the effects of IL-12 on sperm are not well-known, and they should avoid conception during the study period.
Age 18 years or over.
Adequate hematopoietic, renal and hepatic function, defined as:
Absolute neutrophil count greater than or equal to 1000/microL (G-CSF permitted);
Hemoglobin greater than or equal to 9 g/dl (transfusion or erythropoietin permitted);
Platelet count greater than or equal to 100,000/microL;
Creatinine less than or equal to 1.5 X upper limit of normal;
Bilirubin less than or equal to 1.5 X upper limit of normal;
AST/SGOT less than or equal to 2.5 X upper limit of normal;
ALT/SGPT less than or equal to 2.5 X upper limit of normal;
Calculated Creatinine Clearance greater than 60 mL/min.
Karnofsky Performance Status index greater than or equal to 70.
Written signed informed consent.
No HIV infection.
No active malignancy.
No symptomatic cardiac disease or ongoing treatment for same.
No active seizure disorder or ongoing treatment for same.
No pregnancy or lactation.
No surgery during the two weeks prior to the start of IL-12.
No concurrent use of systematic corticosteroids, except for physiologic replacement.
No exposure to any investigational drug within four weeks prior to the start of dosing.
No gastrointestinal bleeding or uncontrolled peptic ulcer disease.
No history of inflammatory bowel disease or autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus.
No other major illness which, in the investigator's judgement, will substantially increase the risk associated with the patient's participation in this study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
Colaboradores e Investigadores
Publicaciones y enlaces útiles
Publicaciones Generales
- Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, Drysdale P, Jouanguy E, Doffinger R, Bernaudin F, Jeppsson O, Gollob JA, Meinl E, Segal AW, Fischer A, Kumararatne D, Casanova JL. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 1998 May 29;280(5368):1432-5. doi: 10.1126/science.280.5368.1432.
- Altare F, Lammas D, Revy P, Jouanguy E, Doffinger R, Lamhamedi S, Drysdale P, Scheel-Toellner D, Girdlestone J, Darbyshire P, Wadhwa M, Dockrell H, Salmon M, Fischer A, Durandy A, Casanova JL, Kumararatne DS. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. J Clin Invest. 1998 Dec 15;102(12):2035-40. doi: 10.1172/JCI4950.
- Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA, Wolf SF, Young D, Clark SC, Trinchieri G. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med. 1991 Apr 1;173(4):869-79. doi: 10.1084/jem.173.4.869.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Atributos de la enfermedad
- Infecciones bacterianas
- Infecciones bacterianas y micosis
- Infecciones por bacterias grampositivas
- Infecciones por Actinomycetales
- Infecciones
- Enfermedades contagiosas
- Infecciones por micobacterias
- Infecciones por Mycobacterium, no tuberculosas
- Efectos fisiológicos de las drogas
- Agentes antineoplásicos
- Factores inmunológicos
- Inhibidores de la angiogénesis
- Agentes moduladores de la angiogénesis
- Sustancias de crecimiento
- Inhibidores del crecimiento
- Adyuvantes, Inmunológicos
- Interleucina-12
Otros números de identificación del estudio
- 990147
- 99-I-0147
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Atypical Mycobacterium Infection
-
Oregon Health and Science UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Heart... y otros colaboradoresReclutamientoComplejo Mycobacterium AviumEstados Unidos
-
Yale UniversityTerminadoInfección, Mycobacterium Avium-Intracelulare
-
Radboud University Medical CenterReclutamientoEnfermedad pulmonar por el complejo Mycobacterium AviumCorea, república de, Estados Unidos, Croacia, Japón, Países Bajos
-
Shanghai Pulmonary Hospital, Shanghai, ChinaKarolinska Institutet; Fudan University; University of Sydney; Shanghai Municipal...ReclutamientoInfecciones por bacterias grampositivas | Infecciones por micobacterias | Infección por Mycobacterium Avium-Intracelulare | Complejo Mycobacterium AviumPorcelana
-
National Institute of Allergy and Infectious Diseases...TerminadoInfección por Mycobacterium Avium-IntracelulareEstados Unidos
-
National Jewish HealthTerminadoInfección por Mycobacterium Avium-intracelulare
-
Mayo ClinicTerminadoComplejo intracelular Mycobacterium Avium (MAC)Estados Unidos
-
Johns Hopkins UniversityReclutamientoComplejo Mycobacterium AviumEstados Unidos
-
The University of Texas Health Science Center at...AbbottTerminadoComplejo Mycobacterium Avium | Micobacterias no tuberculosasEstados Unidos
-
Radboud University Medical CenterReclutamientoEnfermedad pulmonar por el complejo Mycobacterium AviumPaíses Bajos
Ensayos clínicos sobre Interleucina-12
-
Centre Chirurgical Marie LannelongueDesconocido
-
Margaret RagniWyeth is now a wholly owned subsidiary of Pfizer; University of North CarolinaTerminadoEnfermedad de von WillebrandEstados Unidos
-
Assiut UniversityDesconocidoEnfermedad Neonatal
-
Margaret RagniWyeth is now a wholly owned subsidiary of Pfizer; University of North CarolinaTerminadoEnfermedad de von WillebrandEstados Unidos
-
Jenny Craig, Inc.TerminadoAlimentación restringida por tiempoEstados Unidos
-
Stanford UniversityActivo, no reclutandoInsuficiencia cardiacaEstados Unidos
-
Clinique Spécialisée en Allergies de la CapitaleALK-Abelló A/STerminado
-
Afyonkarahisar Health Sciences UniversityActivo, no reclutando
-
VA Office of Research and DevelopmentAún no reclutandoÚlcera de pie diabéticoEstados Unidos
-
University of FloridaNational Institute on Aging (NIA)Reclutamiento